Fadi Nasr, Ahmad Al Ghoche, Saada Diab, Souheil Hallit, Moussa Riachi
Published online 2019 February,
Targeting the immune checkpoint of programmed death ligand 1 (PDL1) and programmed cell death protein 1 (PD-1) with immunotherapy has improved the treatment of many tumors including non small cell lung cancer (NSCLC). Checking PD-L1 status must be done during the course of therapy.
Changes of PD-L1 status with therapy have been described in several cancer subtypes with different treatment modalities including chemotherapy and immunotherapy. Here we present a case report of a locally advanced squamous lung carcinoma patient presenting a decrease of PD-L1 level after chemotherapy.
This case will be added to the few reports describing such changes in
PD-L1 expression after different treatment modalities.
More data are needed to understand the underlying mechanisms and its treatment implications.
Read the full article →
Leave a reply